Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, will collaborate with JSR Corporation, a materials supplier in a variety of technology driven markets, to develop human liver tissue. Through this collaboration, Aspect’s proprietary Lab-on-a-Printer 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.
“Joining forces with the innovative team at JSR offers a great opportunity to develop a predictive and human-relevant liver tissue platform,” said Tamer Mohamed, president and CEO of Aspect Biosystems. “This will help tackle the big problem of unforeseen liver toxicity, enable the modelling of diseases, and ultimately accelerate the development of new medicines. We are committed to forming strategic partnerships to fully unlock the potential of our bioprinting technology and we are excited to launch this new partnered liver program with JSR.”
“This collaboration with Aspect Biosystems is a key step forward in realizing the value of using human-relevant tissue models in drug development,” said Kouji Suzuki, director of JSR-Keio University Medical and Chemical Innovation Center, JSR Corporation. “JSR is currently developing tissue engineering and biomaterials technologies and actively exploring business opportunities in this space. Aspect’s bioprinting technology is at the forefront of engineering functional tissues and we see the potential for this collaboration to deliver real impact in drug efficacy and toxicity testing.”
(Source: Aspect Biosystems)
